Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study – The Lancet Commentaries: Landmark study finds one in two hospitalised COVID-19 patients develop a complication – National Institute for Health Research In-hospital complications associated with COVID-19 – The Lancet CV Complications Common in Hospitalized […]
The post Large cohort study finds one in two hospitalized COVID-19 patients develop a complication. appeared first on Links Medicus.
Advancing precision medicine for acute respiratory distress syndrome – The Lancet Respiratory Medicine Related: Review: Personalized mechanical ventilation in acute respiratory distress syndrome. Seminar | Acute respiratory distress syndrome. M-A of randomized trials: In patients with acute respiratory distress syndrome, there was no difference in mortality between higher vs. lower positive end-expiratory pressure strategies. M-A: […]
The post Position paper: Advancing precision medicine for acute respiratory distress syndrome. appeared first on Links Medicus.
Ethics in extracorporeal life support: a narrative review – Critical Care
The post Review: Ethics in extracorporeal life support. appeared first on Links Medicus.
How the Delta variant achieves its ultrafast spread – Nature Original study: Study shows the viral loads in the Delta infections are ~1000 times higher than those in the earlier strain infections on the day when viruses are firstly detected.
The post How the Delta variant achieves its ultrafast spread – “Viral load is roughly 1,000 times higher in people infected with the Delta variant than those infected with the original coronavirus strain, according to a study in China”. appeared first on Links Medicus.
Related: Increased transmissibility and global spread of SARS-CoV-2 variants of concern – “Estimated transmissibility increases of alpha 29% (95% CI: 24–33), beta 25% (95% CI: 20–30), gamma 38% (95% CI: 29–48) & delta 97% (95% CI: 76–117)”. AND WHO renames COVID-19 variants with the Greek alphabet (i.e., Alpha, Beta, Gamma, etc), making them simple, easy […]
The post What are the Delta, Gamma, Beta and Alpha Covid variants? appeared first on Links Medicus.
Tocilizumab in COVID-19 therapy: who benefits, and how? – The Lancet Related: A living WHO guideline on drugs for covid-19 – interleukin-6 receptor blockers are now recommended for patients with severe or critical covid-19. AND M-A: Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19 – “The 4% absolute risk reduction […]
The post Opinion | Tocilizumab in COVID-19 therapy: who benefits, and how? – the researchers suggest that maybe IL-6 inhibitors should be given only to patients with high IL-6. appeared first on Links Medicus.
Personalized mechanical ventilation in acute respiratory distress syndrome – Critical Care Related: M-A of randomized trials: In patients with acute respiratory distress syndrome, there was no difference in mortality between higher vs. lower positive end-expiratory pressure strategies. AND Seminar | Acute respiratory distress syndrome. AND Short review: Diagnosis and management of acute respiratory distress syndrome […]
The post Review: Personalized mechanical ventilation in acute respiratory distress syndrome. appeared first on Links Medicus.
News release: COVID-19 antibodies persist at least nine months after infection – Imperial College London Original study: SARS-CoV-2 antibody dynamics and transmission from community-wide serological testing in the Italian municipality of Vo’ – Nature Communications
The post COVID-19 antibodies persist at least nine months after infection – “98.8 percent of people infected in February/March showed detectable levels of antibodies in November”. appeared first on Links Medicus.
Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial – The Lancet Diabetes & Endocrinology Commentary: Dapagliflozin in patients with COVID-19: truth or dare – The Lancet Diabetes & Endocrinology
The post RCT: Dapagliflozin in patients with cardiometabolic risk factors hospitalized with COVID-19 – safe, but no statistically significant risk reduction in organ dysfunction or death. appeared first on Links Medicus.
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant – New England Journal of Medicine Commentaries: Study Finds Pfizer And AstraZeneca Vaccines Effective Against The Delta Variant — As Long As You Get Both Doses – Forbes AND Pfizer’s COVID-19 vaccine works very well against the Delta variant — but only after 2 doses – […]
The post Study shows AstraZeneca and Pfizer vaccines are effective against Delta variant, but both doses are needed. appeared first on Links Medicus.